OrthodontiCell

OrthodontiCell is a private clinical-stage dental device company developing a bioelectric stimulation mouthpiece intended to accelerate orthodontic tooth movement and improve post-treatment stabilization for patients using braces or clear aligners. Its lead product, the Tooth Movement Accelerator, is an investigational Class II adjunctive dental device designed to modulate bone-remodeling pathways involved in tooth movement. The company positions itself as a hybrid medical device-biotech business, using patented and patent-pending bioelectric signal sequences to influence protein expression associated with periodontal and alveolar biology. OrthodontiCell has reported prior clinical work in Brazil and is pursuing the FDA De Novo pathway in the United States ahead of commercialization. The business is focused on shortening orthodontic treatment duration, reducing pain, and improving retention outcomes.